Insider Selling: Omeros (NASDAQ:OMER) VP Sells 25,000 Shares

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total value of $463,500.00. Following the transaction, the vice president directly owned 200 shares in the company, valued at approximately $3,708. This represents a 99.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Omeros Stock Performance

OMER traded down $0.04 during mid-day trading on Tuesday, reaching $18.75. The stock had a trading volume of 2,042,181 shares, compared to its average volume of 1,711,567. The firm’s fifty day simple moving average is $12.81 and its two-hundred day simple moving average is $12.08. The stock has a market capitalization of $1.36 billion, a P/E ratio of 14.65 and a beta of 2.54. Omeros Corporation has a 52 week low of $3.94 and a 52 week high of $19.65.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. As a group, analysts expect that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on OMER. HC Wainwright reissued a “buy” rating on shares of Omeros in a report on Monday, July 27th. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Institutional Investors Weigh In On Omeros

Institutional investors have recently made changes to their positions in the stock. State of Wyoming bought a new stake in Omeros in the fourth quarter valued at about $25,000. B. Riley Wealth Advisors Inc. bought a new position in Omeros during the second quarter worth about $32,000. Caitong International Asset Management Co. Ltd bought a new position in Omeros during the fourth quarter worth about $33,000. Assetmark Inc. acquired a new position in shares of Omeros during the 1st quarter worth about $38,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,971 shares during the period. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.